Extracellular vesicles (EVs) are cell membrane-derived compartments that regulate physiology and pathology in the body. Naturally secreted EVs have been well studied in their biogenesis and have been exploited in targeted drug delivery. Due to the limitations on production of EVs, nitrogen cavitation has been utilized to efficiently generate EV-like drug delivery systems used in treating inflammatory disorders. In this short review, we will discuss the production and purification of EVs, and we will summarize what technologies are needed to improve their production for translation. We describe the drugloading processes in EVs and their applications as drug delivery systems for inflammatory therapies, focusing on a new type of EVs made from neutrophil membrane using nitrogen cavitation.
INTRODUCTION
One of the technological breakthroughs of the twentyfirst century is nanotechnology, which allows the assembly of atoms and molecules to form nanoscale and functional materials. Nanomedicine is the application of nanotechnology in medicine and biology [1] . In nanomedicine, drug delivery using nanoparticles (NPs) improves therapies for a wide range of diseases since NPs can efficiently carry and deliver drugs [2] [3] [4] [5] [6] . For example, synthetic NPs made from lipids [7] , polymers [8] , proteins [9] [10] [11] , and metals [12, 13] have been shown to have many applications in drug delivery. Compared to free drugs, drug-loaded nanoparticles possess several advantages, such as improved drug solubility, targeting ability, and longer circulation times [6, 14] . Synthetic nanoparticle properties present several physiological barriers when they are administered in humans. Designing and producing biomimetic nanoparticle-based drug delivery systems are highly needed. Biomimetic NPs might overcome the limitations of synthetic NPs because they are derived from cells or tissues allowing them to escape immune surveillance in the body. For example, extracellular vesicles (EVs) have been explored as drug carriers.
EVs are cell membrane-derived compartments involved in intercellular communications [15] . It has been shown that most eukaryotic cells shed EVs, and subsequently, they mediate delivery of cargos to neighbor cells or distant cells [16] [17] [18] . Such vesicles were first discovered in 1983, when it was shown that multi-vesicular bodies in reticulocytes released vesicles into the extracellular space [19] . The focus of current studies is on purification of EVs derived from various mammalian cells [20] . There are three types of EVs based on their origins and sizes. Exosomes are vesicles with sizes of 30-150 nm that originate from the inward budding of multivesicular bodies. Microvesicles, or exosomes, result from the outward budding of the plasma membrane. The third type of EVs is apoptotic bodies produced by cells undergoing apoptosis. EVs are not only released from mammalian cells but also from prokaryotic cells, such as Gram-positive and Gram-negative bacteria [21, 22] . EVs are complicated and heterogeneous, and thus, it is critical to develop novel strategies to efficiently generate uniform EVs, which is very important in drug delivery applications.
EVs show a great potential as a novel drug delivery platform [23, 24] . EVs harness many features from their parent cells, and therefore, they can possibly be developed as personalized nanomedicine [25, 26] . Moreover, as naturally secreted vesicles, EVs possess many unique properties, including low immunogenicity and toxicity, increased circulation times and protection of RNA or DNA in blood [27, 28] . In this short review article, we will describe the production and purification of EVs and discuss how current technologies can improve extracellular vesicle production. Furthermore, we will address how drugs are efficiently loaded in EVs and their applications in inflammatory therapies, focusing on a new type of EVs made from neutrophil membrane using nitrogen cavitation.
ISOLATION AND PURIFICATION OF EVS
Isolation and purification of EVs are critical for their applications in drug delivery [29] . EVs can be isolated based on their unique properties, such as size, density, shape, and surface proteins. Each technique has its advantages and disadvantages. Here, we review several technologies used to isolate and purify EVs and discuss what new technologies can improve the EV production.
Serial Centrifugations
Exosomes are a major component in EVs and have been well studied. Generally, the methods to isolate exosomes are based on serial centrifugations [30] . In the first step, centrifugation at a low speed removes cell debris, and subsequently, ultracentrifugation at a high g-force is used to separate vesicles based on their density [31] . In addition to centrifugation, a filtration system based on the molecular weight or size of exosomes is also utilized in some studies. Filtration can eliminate cell debris and vesicles larger than 220 nm [32] . Size-based chromatography can also be used to obtain vesicles larger than 50,000 kDa [33] .
Centrifugation-based methods have also been used to isolate EVs from non-mammalian cells, including prokaryotic cells and yeasts. Prokaryotic cells and yeasts can naturally secrete EVs (so-called outer membrane vesicles, OMVs), which play a central role in virulence, pathogenesis, bacterium/yeast physiology, and cellular traffics [17, 34, 35] . In terms of isolating OMVs, the common methods include filtration and ultracentrifugation. For example, a bacterial supernatant is passed through a membrane with the molecular weights from 50 to 100 kDa to remove the majority of non-OMV associated proteins, and ultracentrifugation is performed at 100,000-150,000g to purify OMVs [36, 37] .
Isolation of EVs based on differential centrifugations is summarized in Fig. 1 . The centrifugation-based methods may not separate exosomes from microvesicles because they have a similar size and density [38] . They do, however, have different membrane surface markers, and therefore, exosomes might be further isolated using other techniques. Moreover, micro-fluidics are also used to isolate EVs, but their narrow channels frequently cause clogging [39] , and there is a low yield to generate EVs [40] . Additionally, ultracentrifugation is a time-consuming approach [41] . Therefore, production of EVs using current techniques is difficult to translate EVs in clinic. It is urgent to develop innovative technologies to efficiently produce EVs.
Nitrogen Cavitation
To overcome the issues on scalability, reproducibility, and heterogeneity in producing EVs, Jin et al. [10, 42] have developed a novel approach to generate EV-like nanovesicles with a high yield compared with naturally secreted EVs. The schematic of a preparation procedure is shown in Fig. 2a . Nitrogen cavitation is used to disrupt cells, and subsequently, the broken cell membrane forms nanoscale vesicles. This novel approach includes low centrifugation to remove cell debris, and ultracentrifugation at 100,000g to purify EVs. This method has generated EVs with a high production yield that is 16-fold higher than EVs obtained from their secretion in cell media (Fig. 2b ).
LOADING THERAPEUTICS IN EVS
It has been shown that EVs are ideal carriers in targeted drug delivery, but efficiently loading therapeutics into EVs is still challenging. A lipid bilayer of membrane is a barrier for loading therapeutics inside EVs. Here, we discuss two types of strategies to load therapeutics in EVs: (1) exogenous cargos are loaded into cells during the cell culture, and then, EVs automatically contain cargos during their secretion; (2) exogenous cargos are loaded in preformed EVs.
Loading Exogenous Cargos in Cells
EVs are mediators in cell-cell communication via delivery of RNA or proteins. siRNA or miRNA are entrapped in EVs when they are shed from cells. Subsequently, EVs can be taken up by adjacent cells or distal tissues, and thus, siRNA or miRNA are delivered to the cells. These RNA can silence or activate targeted cells [43] [44] [45] . Based on this concept, siRNA or miRNA could be loaded in cells, and then, the RNA would be capsulated in EVs during their formation in culture media. Another loading strategy is to mix or incubate drugs with cells, and drug-loaded vesicles could be obtained by extrusion of cells [10, 46, 47] . Jang's group [46] produced doxorubicin-loaded nanovesicles by serial extrusions of cells via a membrane filter, and drug-loaded vesicles were purified using a series of density gradient centrifugations.
Loading Exogenous Cargos Inside EVs
EVs can be loaded with various drugs after they are formed, including anti-inflammatory drugs such as curcumin [28] , TPCA-1 [10] , and piceatannol [42] or anti-tumor drugs such as paclitaxel [48] . The loading efficiency depends on temperature and incubation time. Electroporation is also used to load hydrophilic compounds, including small RNA (siRNA). This approach has been applied in both eukaryotic EVs and prokaryotic EVs, based on the changes in membrane electrical potential. Alvarez-Erviti's group reported that exosomes loaded with siRNA by electroporation could deliver GAPDH siRNA specifically to neurons in the brain, resulting in a specific gene knockdown [49] . Another study reported that kinesin spindle protein (KSP)-related siRNA was incorporated into E.coli-derived OMVs for cancer treatment [50] . siRNA loading via electroporation still remains challenging. For example, siRNA molecules aggregate during electroporation, leading to decreased efficacy in transfection. It is noted that electroporation can also cause EV aggregation [51] . Thus, more studies should be conducted to improve the strategies on loading of siRNA into EVs.
Other approaches have also been utilized for loading of therapeutics into EVs, including incubation, sonication, permeabilization, freeze-thaw cycles, and extrusion [52] . The sonication and extrusion result in the highest loading efficiency while increasing the size of EVs. Since the sonication approach disrupts the integrity of EVs, it could possibly influence surface protein redistribution on EVs, resulting in reduced targeting delivery. In summary, the approaches discussed above provide a comprehensive strategy to load therapeutics into EVs for targeted drug delivery. We summarize these strategies in Fig. 3 below.
TARGETING INFLAMED ENDOTHELIUM

Functions of Endothelium and Leukocyte Infiltration
EVs, which are artificial vesicles generated from cell membrane, have emerged as an ideal delivery platform to treat a wide range of diseases. This section will focus on the therapeutic applications of EVs in targeting inflamed endothelium in inflammatory disorders. The endothelium that is located at the interface between blood and tissues regulates vascular physiology and pathology. One of its main functions is to maintain the vascular homeostasis by sensing changes in stimulus and by releasing substances [53] . The endothelium plays an important role in blood vessel functions by producing various signaling molecules, such as vasodilators/vasoconstrictors, inflammatory/anti-inflammatory factors, and procoagulants/anti-coagulants.
Endothelial dysfunction is involved in many diseases such as stroke, hypertension, and cardiovascular diseases [54] . Vascular inflammation is a hallmark of the inflammatory process, including leukocyte adhesion to the endothelium. Leukocyte recruitment at vascular injury sites is a rapid process and is mediated by adhesion molecules highly expressed on endothelium, including P-selectin, E-selectin, intercellular adhesion molecule 1 (ICAM-1), and vascular cell adhesion molecule 1 (VCAM-1). P-selectin is the most active promoter to mediate leukocyte adhesion and transmigration.
Vascular endothelium is strongly involved in leukocyte recruitment, cytokine production, and angiogenesis. Inflamed endothelium is a novel target for drug delivery systems to effectively access diseased sites after they are intravenously administered. Free drugs do not possess the capability to 
Targeting Inflamed Endothelium via Neutrophil MembraneDerived Vesicles
Based on the natural characteristics of neutrophils (a type of leukocyte), neutrophil membrane-derived vesicles have been investigated as drug carriers to target inflamed sites. The hypothesis is that nanovesicles derived from neutrophil membrane could bind inflamed endothelium since they possess all adhesion molecules on their parent cells (neutrophils). To prove this hypothesis, the question was addressed whether neutrophil membrane-formed nanovesicles can target inflamed vasculature [10] . HL-60 cells (human promyelocytic leukemia cells) obtained from acute myeloid leukemia patients were chosen as the model cells, since they are capable to differentiate to granulocyte-like cells (neutrophils) after they are treated with chemical reagents, such as DMSO (dimethyl sulfoxide). In the study, nitrogen cavitation was used to prepare membrane-derived nanovesicles. Nanovesicle-targeting ability was first tested by identifying the expression of integrin β 2 , a key adhesion molecule on the neutrophil surface. It was observed that nanovesicles showed the expression of integrin β 2 as their parent cells did, and by contrast, red blood cells and their nanovesicles did not express integrin β 2 (Fig. 5a ). Nanovesicles made from red blood cells were used as the control to investigate the endothelium targeting of HL 60-derived nanovesicles. Further, in vitro experiments on the uptake of nanovesicles in human umbilical vein cells (HUVECs) and intravital microscopy of activated endothelium in a mouse cremaster venule confirmed the binding and uptake of nanovesicles in the endothelium (Fig. 5b) . TPCA-1 (2-[(Aminocarbonyl)amino]-5-(4-fl uorophyneyl)-3-thiophenecarboxamide), a NF-κB inhibitor, can reduce the expression of adhesion molecules on endothelium and decrease neutrophil adhesion and transmigration. After TPCA-1 was loaded into nanovesicles, TPCA-1 loaded nanovesicles were given to a mouse to investigate whether nanovesicles could serve as a drug carrier to deliver therapeutics to inflamed vasculature. In a lipopolysaccharide (LPS)-induced acute lung inflammation model, neutrophil infiltration and cytokines (TNF-α and IL-6) were dramatically decreased in bronchoalveolar lavage fluid (BALF) after administration of TPCA-1-nanovesicles, indicating that neutrophil-derived nanovesicles can prevent inflammation (Fig. 5c, d) .
After confirming that neutrophil membrane-derived vesicles can target inflamed endothelium, Jin et al. published another study where they compared the composition of HL-60 cell membrane-derived vesicles generated from nitrogen cavitation (NC-EVs) with that of EVs isolated from cell culture medium, so-called naturally secreted EVs (NS-EVs) [42] . It was shown that the production of NC-EVs increased 16-fold compared with that of NS-EVs (Fig. 2b) , and protein analysis (Western blot) of EVs generated by nitrogen cavitation and natural secretion indicated that NC-EVs contained fewer subcellular organelles, such as lysosomes and endoplasmic reticulum. Both NC-EVs and NS-EVs expressed integrin β 2 , but NC-EVs highly expressed integrin β 2 (data not shown here). The proteomics study [42] further showed that some membrane proteins were present in both NC-EVs and NS-EVs, but there was a portion of proteins that were not found in either in NC-EVs or in NS-EVs. This finding is consistent with the conclusion that nitrogen cavitation can efficiently eliminate organelles in the preparation of NC-EVs compared with that in NS-EVs. To examine the therapy using neutrophil-derived EVs, piceatannol was loaded into EVs by remote loading based on the pH gradient (Fig. 6a) . Piceatannol-loaded NC-EVs reduced lung edema and decreased leukocyte infiltration in the lung in an LPSinduced lung inflammation model (Fig. 6b) . Further studies showed that piceatannol-loaded NC-EVs increased mouse survival by 80% in an LPS-induced mouse sepsis model compared to the group without treatment (Fig. 6c) . This study showed that neutrophil membrane-derived nanovesicles can target inflamed endothelium to reverse sepsis-induced inflammation. The nitrogen cavitation technique offers the potential to translate NC-EVs in the clinic as neutrophils are the most abundant white blood cells in humans. 
Hybrid EV-like Delivery Platforms Target Inflamed Endothelium
In addition to neutrophil membrane-derived EVs, other nanovesicle platforms have also been studied for targeting inflamed endothelium. Erythrocyte membrane-derived microvesicle/microparticles (MPs) generated from human erythrocytes enhanced delivery of drugs to endothelial cells for sickle cell disease (SCD) treatment [55] . MPs are enriched with heme, and an immuno-histology experiment showed that MPs adhere to endothelial cells, and transfer heme to cells. In a transgenic S-Antilles-D Punjab Hb-expressing (SAD) mouse, heme-enriched MPs triggered vaso-occlusions in kidney. The study suggests that MPs made from erythrocytes demonstrate the targeting and therapeutic abilities in SCD. Since erythrocytes do not express the adhesion molecules to the vasculature, it is not clear how MPs target inflamed endothelium.
In another study, exosomes derived from human U937 monocytic cells and Raw264.7 cells (immortalized mouse macrophages) were able to target tumor endothelium and deliver chemotherapeutics (such as doxorubicin) to tumors. The doxorubicin-loaded exosomes displayed the targeting ability to endothelial cells via lymphocyte function-associated antigen 1 (LFA-1). Due to the higher expression of adhesion molecules on tumor endothelium, doxorubicin-loaded exosomes showed the increased doxorubicin deposition in tumor tissues. In a CT26 tumor-inoculation mouse model, doxorubicin-loaded exosomes reduced the tumor growth and increased the mouse survival rate compared to doxorubicinloaded liposomes (control) and doxorubicin-loaded nanovesicles without a targeting ligand (LFA-1), indicating the exosomes can target tumor endothelium [56] .
Biomimetic liposomes have also been explored. For example, surface proteins from leukocyte plasma membrane were extracted, and then the proteins were incorporated onto the liposome surface [57] . The vesicles, so-called leukosomes displayed targeting ability to inflamed endothelia, and retained physicochemical properties of liposomes. While this strategy offers the potential to incorporate any targeting ligands to liposomes, the protein orientation on the surface and targeting activities may require further study. In addition, cellular membranes isolated from leukocytes were used to coat nanoporous silicon particles for targeting inflamed endothelium. This platform can actively bind to tumor endothelium in cancer therapies [58] . A similar strategy was exploited to add lymphocyte functionassociated antigen (LFA)-1 on super paramagnetic iron oxide (SPIO) nanoparticles, and this system was able to target inflamed vasculature in tumor tissues [59] .
CONCLUSION AND PERSPECTIVE
EVs are natural membrane vesicles that are involved in intercellular communications in prokaryotic and eukaryotic cells. EVs are secreted from cells and possess unique characteristics of intercellular interactions, and so they have become an ideal delivery system in targeted drug delivery. Naturally secreted EVs from cells or tissues remain difficult to be translated in the clinic because their purification is time-consuming. Moreover, it is unlikely that their production is scalable and reproducible. Another reason is that the composition and size of EVs are highly heterogeneous. Therefore, it is urgent to develop novel concepts and strategies to generate EVs for translation.
Recently, nitrogen cavitation has been exploited to generate EV-like nanovesicles. Nitrogen cavitation generates mechanic force in a chamber to rapidly break cells to form cell membrane nanoscale vesicles. Cryo-TEM and proteomics results show that neutrophil membrane-formed nanovesicles generated by nitrogen cavitation are similar to the EVs made from natural secretion [10, 42] . However, nitrogen cavitation dramatically increases the production of EVs compared to natural secretion. Furthermore, EVs made by nitrogen cavitation contain fewer genes, intracellular proteins, and organelles in their parent cells. Thus, EVs could be translational in targeted drug delivery in the future.
Neutrophils are the most abundant white blood cells in humans (50-75%) [60] . Here, we have demonstrated that nitrogen cavitation can efficiently generate neutrophilderived EVs and that they can specifically target inflamed vasculature. In an acute lung inflammation/injury mouse model, it has been shown that drug-loaded neutrophil-derived EVs can attenuate lung inflammation and injury. Other recent studies have also demonstrated that hybrid EV-like liposomes can target inflamed vasculature in tumor tissues. Activated endothelium is involved in the pathogenesis of most diseases [61, 62] , such as thrombosis, neurological disorders, atherosclerosis, acute lung injury, and cancer. Vascular targeting based on neutrophil-derived EVs is a novel strategy to improve current therapies in many inflammatory diseases.
